287 results
8-K
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
services, and (5) reimbursement for up to $15,000 of legal fees.
The Letter Agreement also provides for a one-year consulting arrangement with Ms
8-K
EX-10.1
ALNY
Alnylam Pharmaceuticals Inc
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
as of the end of your Consulting Period and related agreements entered
into with you under the Company’s equity plans; (c) your right to reimbursement
8-K
EX-99.1
8pj1fn9
15 Feb 24
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
edl9msb
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
EX-99.1
m24yn1nwp4krioyo5
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
qi0s0b8qw act
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
EX-99.1
nda 70rge38lfbed
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
EX-99.1
mlmcunnvd8ggzugcyhy7
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
5jjyg7w
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
EX-99.1
ba3 ua7m4xeuu
4 May 23
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
jbiawq8vni
27 Oct 22
Results of Operations and Financial Condition
8:10am